胡梦雪，许斌，于金明，宋启斌, Xu Bin Yu Jinming Song Qibin Hu Mengxue
{"title":"PD-L1/TGF-β双功能抑制剂融合蛋白M7824研究进展","authors":"胡梦雪，许斌，于金明，宋启斌, Xu Bin Yu Jinming Song Qibin Hu Mengxue","doi":"10.3760/CMA.J.ISSN.1673-422X.2019.05.006","DOIUrl":null,"url":null,"abstract":"With the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, the second generation of combined immunosuppressive agents emerge as the times require. As a bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein, M7824 can antagonize PD-L1 pathway and trap TGF-β at the same time, which can effectively enhance the immune response and reduce the occurrence of immune escape and drug resistance. The drug has achieved remarkable results in many preclinical studies, however, the indications, safety and efficacy still need to be confirmed by large-scale clinical research data. \n \n \nKey words: \nRecombinant fusion proteins; Transforming growth factor β; PD-L1; M7824","PeriodicalId":16120,"journal":{"name":"国际肿瘤学杂志","volume":"27 1","pages":"281-284"},"PeriodicalIF":0.0000,"publicationDate":"2019-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PD-L1/TGF-β双功能抑制剂融合蛋白M7824研究进展\",\"authors\":\"胡梦雪，许斌，于金明，宋启斌, Xu Bin Yu Jinming Song Qibin Hu Mengxue\",\"doi\":\"10.3760/CMA.J.ISSN.1673-422X.2019.05.006\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"With the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, the second generation of combined immunosuppressive agents emerge as the times require. As a bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein, M7824 can antagonize PD-L1 pathway and trap TGF-β at the same time, which can effectively enhance the immune response and reduce the occurrence of immune escape and drug resistance. The drug has achieved remarkable results in many preclinical studies, however, the indications, safety and efficacy still need to be confirmed by large-scale clinical research data. \\n \\n \\nKey words: \\nRecombinant fusion proteins; Transforming growth factor β; PD-L1; M7824\",\"PeriodicalId\":16120,\"journal\":{\"name\":\"国际肿瘤学杂志\",\"volume\":\"27 1\",\"pages\":\"281-284\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际肿瘤学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.05.006\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-422X.2019.05.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
With the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors, the second generation of combined immunosuppressive agents emerge as the times require. As a bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein, M7824 can antagonize PD-L1 pathway and trap TGF-β at the same time, which can effectively enhance the immune response and reduce the occurrence of immune escape and drug resistance. The drug has achieved remarkable results in many preclinical studies, however, the indications, safety and efficacy still need to be confirmed by large-scale clinical research data.
Key words:
Recombinant fusion proteins; Transforming growth factor β; PD-L1; M7824
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
